← All trials
NCT03448159
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2018
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 176
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- Applied Health Research CentreCollaborator
- Brain CanadaCollaborator
- Dalhousie UniversityCollaborator
- Dalhousie UniversityOverall official - principal investigator
- Memorial University of NewfoundlandCollaborator
- Memorial University of NewfoundlandOverall official - principal investigator
- University of Western OntarioCollaborator
- Riverview Health Centre FoundationCollaborator
- University of TorontoCollaborator
- University of TorontoOverall official - principal investigator
- University of TorontoOverall official - principal investigator
- University of British ColumbiaCollaborator
- University of British ColumbiaOverall official - principal investigator
- University of CalgaryCollaborator
- University of CalgaryOverall official - principal investigator
- University of TorontoOfficial
- University of TorontoOfficial
- Dalhousie UniversityOfficial
- University of British ColumbiaOfficial
- University of CalgaryOfficial
- Memorial University of NewfoundlandOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.